Amarin slides despite fourth quarter beat on strong Vascepa demand » 11:1902/2602/26/20
TEVA, HKMPF, HKMPY, RDY, AMRN
Shares of Amarin (AMRN)…
H.C. Wainwright reiterates $51 price target on Amarin shares post Q4 results » 07:2002/2602/26/20
AMRN, RDY, HKMPY, TEVA
H.C. Wainwright analyst…
H.C. Wainwright analyst Andrew Fein reiterates a Buy rating on Amarin (AMRN) with a $51 price target following the company's Q4 results. Amarin has asserted its confidence both in its intellecutal property and its intention to vigorously defend its patents, Fein tells investors in a research note. The analyst points out that two of the original four Abbreviated New Drug Application filers currently remain, Dr. Reddy's (RDY) and Hikma (HKMPY), while Teva (TEVA) has settled with Amarin to enter the market in August 2029 and Apotex has determined not to litigate. Fein continues to believe in the feasibility of settlement with a court decision expected in March. Meanwhile, Vascepa's positive commercial traction as an omega-3 therapeutic "represents the tip of the iceberg for the treatment," the analyst writes in a research note.
|Over a week ago|
Amarin rises as Citi says Buy on selloff, accelerating Vascepa sales » 11:2002/1802/18/20
AMRN, RDY, HKMPF
Shares of Amarin (AMRN)…
Dr. Reddy's to acquire select business divisions of Wockhardt in India » 05:2302/1202/12/20
Dr. Reddy's Laboratories announced that it has entered into a definitive agreement with Wockhardt Limited to acquire select divisions of its branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives for a consideration of Rs.1850 Crores.The business comprises of a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines, which would transfer to Dr. Reddy's along with related sales and marketing teams; and the manufacturing plant located in Baddi, Himachal Pradesh with all plant employees. The business undertaking is being transferred on a slump sale basis. The transaction is expected to be closed in the first quarter of the financial year 2020-21.
Dr. Reddy's announces launch of Trientine Hydrochloride Capsules USP in U.S. » 05:3002/0702/07/20
Dr. Reddy's announced the launch of Trientine Hydrochloride Capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine Capsules, approved by the FDA. Dr. Reddy's Trientine Hydrochloride Capsules USP, 250 mg are available in 100 count bottles.
|Over a month ago|
Jefferies confident Amarin will win patent trial, sees up to 20% rally » 09:1801/2901/29/20
AMRN, RDY, HKMPF
Court proceedings for the…
Court proceedings for the Amarin (AMRN) versus Dr. Reddy's (RDY) and Hikma Pharmaceuticals (HKMPF) case have ended, following seven days of expert witness testimony, Jefferies analyst Michael Yee tells investors in a research note. The judge did not provide a preliminary ruling or hint at which way she is ruling, but she did state the written ruling will be made by March 31, Yee points out. With the proceedings completed, and Dr. Reddy's and Hikma having presented their best case, Yee is now more confident that Amarin is likely to prevail, "removing the chief overhang on the stock." Amarin shares have been relatively range bound the last month despite positive news on the competitive front with two key competitor trials having failed, Yee contends. He attributes this to uncertainty associated with the patent trial and the potential risk for Reddy's and Hikma, two prospective generics for Amarin's Vascepa, to present some "bombshell" evidence. However, the analyst now thinks it will be hard for the judge to not rule in favor of Amarin. Yee sees the stock up 10%-20% on a positive ruling and keeps a Buy rating on Amarin with a $30 price target. The stock closed Tuesday at $20.26.
Dr. Reddy's downgraded to Outperform from Buy at CLSA » 05:5501/2801/28/20
CLSA analyst Alok Dalal…
CLSA analyst Alok Dalal downgraded yesterday afternoon Dr. Reddy's to Outperform from Buy with a price target of INR 3,450. The company's EBITDA beat fiscal Q3 expectations but a large impairment drove a net profit miss, Dalal tells investors in a post-earnings research note. The stock's valuation "offers limited room to slip up" and already "bakes in positives," the analyst contends.
Dr. Reddy's downgraded to Outperform from Buy at CLSA » 15:5601/2701/27/20
CLSA downgraded Dr.…
CLSA downgraded Dr. Reddy's to Outperform from Buy.
Amarin seen in 'good position' as Vascepa patent trial proceeds » 11:5901/2101/21/20
Following the fourth day…
Amarin in 'good position' as 'heated' patent trial continues, says Jefferies » 08:1501/1601/16/20
Jefferies analyst Michael…
Jefferies analyst Michael Yee said the third day of Amarin's (AMRN) patent trial versus Hikma and Dr. Reddy's (RDY) focused on the claim of nonobviousness and examination of the defense's witness, adding that cross-examination "went well" in his view for Amarin. Barring some new evidence or "radical interpretation" by Judge Miranda Du, Yee thinks Amarin is in a "good position" and believes the company is likely to prevail on upholding the patent given his view that the burden of proof is "already high" for obviousness. The analyst, who noted that the trial will last until the end of January and a decision is expected around March or April, has a Buy rating on Amarin shares.